Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

PURPOSE: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Yonsei Med J
Glavni autori: Kwon, Hyeok Chan, Kim, Minyoung Kevin, Song, Jason Jungsik, Park, Yong-Beom, Lee, Sang-Won
Format: Artigo
Jezik:Inglês
Izdano: Yonsei University College of Medicine 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393299/
https://ncbi.nlm.nih.gov/pubmed/32734735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.8.712
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items